Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adults 18-70 years of age;~* HBeAg-negative chronic hepatitis B for \>/=6 months;~* liver disease consistent with chronic hepatitis B.~Exclusion Criteria:~* interferon-based, systemic anti-HBV, antiviral, anti-neoplastic, or immunomodulatory therapy \</=12 months before first dose of study drug;~* non-responders to previous interferon therapy;~* co-infection with hepatitis A, C or D, or with human immunodeficiency virus (HIV);~* hepatocellular cancer;~* compensated (Child A, score 6) or decompensated liver disease (Child B or C).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PEG-IFN48 (Type: EXPERIMENTAL): Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks.
- PEG-IFN96 (Type: EXPERIMENTAL): Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by another 48 weeks of PEG-IFN treatment (total 96 weeks of treatment).
- PEG-IFN+LAM96 (Type: EXPERIMENTAL): Treatment with PEG-IFN and lamivudine in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by 48 weeks of only PEG-IFN treatment (total 96 weeks of treatment).

Based on this trial design, predict the completion outcome and termination type (if applicable).